TY - JOUR
T1 - Asthma Across the Ages
T2 - Adults
AU - Busse, Paula J.
AU - McDonald, Vanessa M.
AU - Wisnivesky, Juan P.
AU - Gibson, Peter G.
N1 - Funding Information:
The preparation of this article was supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship to P.G.G. (grant no. APP1155810). P.J.B. is supported by National Institutes of Health/National Heart, Lung, and Blood Institute (grant nos. R01HL131418, R01HL129198, and R01 HL142749-01). The funding sources had no role in the writing of the report or in the decision to submit the article for publication.Conflicts of interest: P. J. Busse reports personal fees, outside of the submitted work, from CSL Behring, Takada, Pharming, Pearl Therapeutics, BioCryst, CVS Health, Novartis, AstraZeneca, and GlaxoSmithKline. V. M. McDonald reports personal fees from AstraZeneca, GlaxoSmithKline, and Menarini and grants from AstraZeneca and GlaxoSmithKline, outside the submitted work. J. P. Wisnivesky has received honorarium from GlaxoSmithKine, Bannok, and Sanofi and an institutional grant from Sanofi. P. G. Gibson reports personal fees from AstraZeneca, GlaxoSmithKline, and Novartis and grants from AstraZeneca and GlaxoSmithKline, outside the submitted work.
Funding Information:
The preparation of this article was supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship to P.G.G. (grant no. APP1155810 ). P.J.B. is supported by National Institutes of Health/National Heart, Lung, and Blood Institute (grant nos. R01HL131418 , R01HL129198 , and R01 HL142749-01 ). The funding sources had no role in the writing of the report or in the decision to submit the article for publication.
Publisher Copyright:
© 2020
PY - 2020/6
Y1 - 2020/6
N2 - Asthma is a common disease affecting approximately 300 million people worldwide, across all age ranges. Despite advances in asthma outcomes of the last few decades, there remains room for improvement in asthma management and for patient outcomes, particularly in older patients. The heterogeneity of asthma is now well recognized, and is known to complicate response to treatment and patient behavior and impact health outcomes. Asthma and its heterogeneity change according to age. Asthma affects people differently across the life span. In adults, prevalence is highest among those in middle age; however, mortality is greater in the older age group. In this clinical commentary, we describe how age impacts asthma prevalence and incidence, outcomes, disease expression, and approach to management in adulthood and in older patients.
AB - Asthma is a common disease affecting approximately 300 million people worldwide, across all age ranges. Despite advances in asthma outcomes of the last few decades, there remains room for improvement in asthma management and for patient outcomes, particularly in older patients. The heterogeneity of asthma is now well recognized, and is known to complicate response to treatment and patient behavior and impact health outcomes. Asthma and its heterogeneity change according to age. Asthma affects people differently across the life span. In adults, prevalence is highest among those in middle age; however, mortality is greater in the older age group. In this clinical commentary, we describe how age impacts asthma prevalence and incidence, outcomes, disease expression, and approach to management in adulthood and in older patients.
KW - Aging
KW - Asthma
KW - Management
UR - http://www.scopus.com/inward/record.url?scp=85085559912&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.03.044
DO - 10.1016/j.jaip.2020.03.044
M3 - Article
C2 - 32499032
AN - SCOPUS:85085559912
SN - 2213-2198
VL - 8
SP - 1828
EP - 1838
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -